Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric

Related Experiment Video

Updated: Sep 27, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Joseph D Tobias1, Kelly Groeper, John W Berkenbosch

  • 1Department of Anesthesiology, University of Missouri, Columbia, MO 65212, USA. Tobiasj@health.missouri.edu

Southern Medical Journal
|February 27, 2003
PubMed

Insights

Recombinant factor VIIa (rVIIa) effectively treats pediatric coagulation dysfunction, even when other treatments fail. This study shows significant improvements in clotting times with no adverse effects, warranting further research.

Area of Science:

  • Pediatric Hematology
  • Hemostasis and Thrombosis
  • Critical Care Medicine

Background:

  • Coagulation dysfunction is a critical issue in pediatric patients.
  • Standard treatments like fresh frozen plasma may not always be effective.
  • Recombinant factor VIIa (rVIIa) is a potential therapeutic option.

Purpose of the Study:

  • To evaluate the efficacy of recombinant factor VIIa (rVIIa) in treating coagulation dysfunction in pediatric patients.
  • To assess the safety and effectiveness of rVIIa in a pediatric intensive care or operating room setting.

Main Methods:

  • Retrospective review of pediatric patients treated with rVIIa.
  • Inclusion of case series from existing literature.
  • Analysis of coagulation parameters before and after rVIIa administration.

Main Results:

  • Ten pediatric patients received 22 doses of rVIIa.
  • Seven patients showed no improvement with prior fresh frozen plasma and cryoprecipitate.
  • Significant reductions in prothrombin time, international normalized ratio, and partial thromboplastin time were observed post-rVIIa.
  • No adverse effects were reported during treatment.

Conclusions:

  • Recombinant factor VIIa (rVIIa) effectively reverses coagulation disturbances in pediatric patients.
  • rVIIa demonstrates therapeutic potential when conventional treatments like fresh frozen plasma have failed.
  • Prospective, randomized trials are recommended to further validate these findings.
Abstract

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...